Lifesci Capital Analyst Recommendations & Stock Picks

Name: Community Performance Rating
Item: Lifesci Capital
Rating: 2.4
Author: MarketBeat

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Lifesci Capital. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Lifesci Capital.

Company	Date	Action	Brokerage	Analyst	Rating	Price Target	Impact on Price
PYXS Pyxis Oncology	4/26/2023	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		Low
OLMA Olema Pharmaceuticals	4/26/2023	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		Low
INBX Inhibrx	4/26/2023	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Low
AVDL Avadel Pharmaceuticals	4/26/2023	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Low
ALXO ALX Oncology	4/26/2023	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		Low
IRON Disc Medicine Opco	4/24/2023	Reiterated by	Lifesci Capital	Analyst R. Katkhuda	Outperform		Low

BLU BELLUS Health	4/18/2023	Downgraded by	Lifesci Capital	Analyst S. Slutsky	Outperform -> Market Perform		N/A
BLU BELLUS Health	4/18/2023	Downgraded by	Lifesci Capital	Analyst S. Slutsky	Outperform -> Market Perform		Low
AKRO Akero Therapeutics	4/11/2023	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Low
IFRX InflaRx	4/5/2023	Upgraded by	Lifesci Capital		Market Perform -> Outperform		Low
BTTX Better Therapeutics	3/31/2023	Downgraded by	Lifesci Capital	Analyst R. Rakhit	Outperform -> Market Perform		Low
CRNX Crinetics Pharmaceuticals	3/27/2023	Reiterated by	Lifesci Capital	Analyst C. Jubinville	Outperform		Low
OBIO Orchestra BioMed	3/8/2023	Reiterated by	Lifesci Capital	Analyst R. Rakhit	Outperform		Low
ELVN Enliven Therapeutics	3/7/2023	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		Low
RAIN Rain Oncology	1/6/2023	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		Low
MLTX MoonLake Immunotherapeutics	12/21/2022	Reiterated by	Lifesci Capital	Analyst R. Katkhuda	Outperform		N/A
PYXS Pyxis Oncology	12/1/2022	Reiterated by	Lifesci Capital	Analyst A. Evertts	Outperform		Low
ATXS Astria Therapeutics	11/28/2022	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		Low
ALXO ALX Oncology	11/8/2022	Reiterated by	Lifesci Capital	Analyst A. Evertts	Outperform		Low
AKLI Akili	9/6/2022	Reiterated by	Lifesci Capital	Analyst R. Rakhit	Outperform		Low
VYNE VYNE Therapeutics	8/12/2022	Downgraded by	Lifesci Capital	Analyst P. Dolezal	Outperform -> Market Perform		Low
LRMR Larimar Therapeutics	8/12/2022	Upgraded by	Lifesci Capital	Analyst P. Dolezal	Market Perform -> Outperform		Low
TNYA Tenaya Therapeutics	6/16/2022	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Low
VERA Vera Therapeutics	3/28/2022	Reiterated by	Lifesci Capital	Analyst R. Katkhuda	Outperform		Low
ELDN Eledon Pharmaceuticals	3/25/2022	Reiterated by	Lifesci Capital	Analyst R. Katkhuda	Outperform		Medium
LRMR Larimar Therapeutics	2/16/2022	Downgraded by	Lifesci Capital	Analyst Patrick Dolezal	Outperform -> Market Perform	$3.00	Medium
BTTX Better Therapeutics	12/27/2021	Reiterated by	Lifesci Capital	Analyst R. Rakhit	Outperform		High
VERV Verve Therapeutics	12/22/2021	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		High
ALLK Allakos	12/22/2021	Downgraded by	Lifesci Capital	Analyst S. Slutsky	Outperform -> Market Perform		High
NNOX Nano-X Imaging	11/17/2021	Downgraded by	Lifesci Capital	Analyst R. Rakhit	Outperform -> Market Perform		Low
VTYX Ventyx Biosciences	11/15/2021	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		High
ALXO ALX Oncology	11/4/2021	Reiterated by	Lifesci Capital	Analyst A. Evertts	Outperform		Medium
PYXS Pyxis Oncology	11/2/2021	Reiterated by	Lifesci Capital	Analyst A. Evertts	Outperform		Low
RCKT Rocket Pharmaceuticals	10/24/2021	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Low
DRIO DarioHealth	8/26/2021	Reiterated by	Lifesci Capital	Analyst R. Rakhit	Outperform		High
VRDN Viridian Therapeutics	8/24/2021	Reiterated by	Lifesci Capital	Analyst R. Katkhuda	Outperform		Low
LRMR Larimar Therapeutics	8/4/2021	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Medium
OLMA Olema Pharmaceuticals	6/21/2021	Reiterated by	Lifesci Capital	Analyst A. Evertts	Outperform		High
NNOX Nano-X Imaging	6/3/2021	Reiterated by	Lifesci Capital	Analyst R. Rakhit	Outperform		High
ADVM Adverum Biotechnologies	4/29/2021	Downgraded by	Lifesci Capital	Analyst P. Dolezal	Outperform -> Market Perform		High

ELDN Eledon Pharmaceuticals	3/18/2021	Reiterated by	Lifesci Capital	Analyst R. Katkhuda	Outperform		High
COGT Cogent Biosciences	1/4/2021	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		N/A
CLDX Celldex Therapeutics	11/17/2020	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		High
BLU BELLUS Health	11/12/2020	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		N/A
BLU BELLUS Health	11/12/2020	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		Medium
TARS Tarsus Pharmaceuticals	11/10/2020	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Medium
AVDL Avadel Pharmaceuticals	11/9/2020	Reiterated by	Lifesci Capital	Analyst D. Sherman	Outperform		Low
ADVM Adverum Biotechnologies	11/5/2020	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Medium
IFRX InflaRx	10/30/2020	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Market Perform		Low
ALLK Allakos	10/22/2020	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		Low
MEIP MEI Pharma	10/21/2020	Reiterated by	Lifesci Capital	Analyst A. Evertts	Outperform		Medium
RCKT Rocket Pharmaceuticals	10/16/2020	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Low
INBX Inhibrx	10/15/2020	Reiterated by	Lifesci Capital	Analyst A. Evertts	Outperform		Medium
IMVT Immunovant	10/6/2020	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		High
VYNE VYNE Therapeutics	10/2/2020	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		High
CBAY CymaBay Therapeutics	9/29/2020	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Medium
ALXO ALX Oncology	9/30/2020	Reiterated by	Lifesci Capital	Analyst A. Evertts	Outperform		Low
CRTX Cortexyme	9/24/2020	Reiterated by	Lifesci Capital	Analyst D. Sherman	Outperform		High

MarketBeat Community Rating for Lifesci Capital

Community Ranking:		2.4 out of 5 ( 2.4 of 5 stars)
Outperform Votes:		2,501 (Vote Outperform)
Underperform Votes:		2,749 (Vote Underperform)
Total Votes:		5,250

MarketBeat's community ratings are surveys of what our community members think about Lifesci Capital and other research firms. Vote "Outperform" if you believe Lifesci Capital's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Lifesci Capital's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days.

Stock Ratings Reports and Tools

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Ratings for Popular Stocks:

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Lifesci Capital Analyst Recommendations & Stock Picks

MarketBeat Community Rating for Lifesci Capital

Stock Ratings Reports and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info